Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imat...

Descripción completa

Detalles Bibliográficos
Autores principales: Reilley, Matthew J., Bailey, Ann, Subbiah, Vivek, Janku, Filip, Naing, Aung, Falchook, Gerald, Karp, Daniel, Piha-Paul, Sarina, Tsimberidou, Apostolia, Fu, Siqing, Lim, JoAnn, Bean, Stacie, Bass, Allison, Montez, Sandra, Vence, Luis, Sharma, Padmanee, Allison, James, Meric-Bernstam, Funda, Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394629/
https://www.ncbi.nlm.nih.gov/pubmed/28428884
http://dx.doi.org/10.1186/s40425-017-0238-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394629/
https://www.ncbi.nlm.nih.gov/pubmed/28428884
http://dx.doi.org/10.1186/s40425-017-0238-1

Ejemplares similares